Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

15.8%

73 terminated/withdrawn out of 463 trials

Success Rate

77.2%

-9.4% vs industry average

Late-Stage Pipeline

1%

3 trials in Phase 3/4

Results Transparency

41%

101 of 247 completed trials have results

Key Signals

73 recruiting101 with results46 terminated27 withdrawn

Enrollment Performance

Analytics

N/A
151(42.5%)
Phase 1
105(29.6%)
Phase 2
73(20.6%)
Early Phase 1
23(6.5%)
Phase 4
2(0.6%)
Phase 3
1(0.3%)
355Total
N/A(151)
Phase 1(105)
Phase 2(73)
Early Phase 1(23)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (463)

Showing 20 of 463 trials
NCT05279027Early Phase 1Active Not Recruiting

Zr89 + PET Companion Trial

Role: lead

NCT07517666Not ApplicableEnrolling By Invitation

Genetic Information for Families After Tumor Testing Study

Role: lead

NCT02732171Not ApplicableRecruiting

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

Role: lead

NCT05832008Not ApplicableCompleted

Increasing Adherence to Lung Cancer Screening

Role: lead

NCT01352429Active Not Recruiting

Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer

Role: lead

NCT03729518Not ApplicableCompleted

TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck

Role: lead

NCT05952141Not ApplicableRecruiting

Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana

Role: lead

NCT07715188Not ApplicableRecruiting

Low Dose Radiotherapy for Osteoarthritis

Role: lead

NCT01985919Completed

Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

Role: lead

NCT05331625Not ApplicableActive Not Recruiting

Understanding Quality of Life Among Patients With Cancer Receiving Palliative Care

Role: lead

NCT03083288Phase 1Active Not Recruiting

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer

Role: lead

NCT07700121Early Phase 1Not Yet Recruiting

PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma

Role: lead

NCT07578467Phase 1Not Yet Recruiting

Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs

Role: lead

NCT04827862Phase 2Active Not Recruiting

RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy

Role: lead

NCT04499534Active Not Recruiting

BRCA1/2 Flu Vaccine

Role: lead

NCT02159742Active Not Recruiting

Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases

Role: lead

NCT03477513Not ApplicableCompleted

Personalized Radiation Therapy for GBM

Role: lead

NCT06551116Recruiting

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Role: lead

NCT06177795Not ApplicableCompleted

Increasing Screening for Cancer Using EHR-Nudges

Role: lead

NCT02471170Enrolling By Invitation

Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases

Role: lead